Genetic markers in lung cancer diagnosis: a review
K Wadowska, I Bil-Lula, Ł Trembecki… - International journal of …, 2020 - mdpi.com
Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of
cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are …
cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are …
PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around
A Gkountakos, G Sartori, I Falcone, G Piro, L Ciuffreda… - Cancers, 2019 - mdpi.com
Lung cancer is the most common malignancy and cause of cancer deaths worldwide, owing
to the dismal prognosis for most affected patients. Phosphatase and tensin homolog deleted …
to the dismal prognosis for most affected patients. Phosphatase and tensin homolog deleted …
An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness
L Liu, T Tao, S Liu, X Yang, X Chen, J Liang… - Nature …, 2021 - nature.com
Notch signaling represents a key mechanism mediating cancer metastasis and stemness.
To understand how Notch signaling is overactivated to couple tumor metastasis and self …
To understand how Notch signaling is overactivated to couple tumor metastasis and self …
Needle biopsy adequacy in the era of precision medicine and value-based health care
KPH Pritzker, HJ Nieminen - Archives of pathology & …, 2019 - meridian.allenpress.com
Context.—Needle biopsy of diseased tissue is an essential diagnostic tool that is becoming
even more important as precision medicine develops. However, the capability of this …
even more important as precision medicine develops. However, the capability of this …
A Canadian guideline on the use of next-generation sequencing in oncology
S Yip, A Christofides, S Banerji, MR Downes… - Current …, 2019 - pmc.ncbi.nlm.nih.gov
Rapid advancements in next-generation sequencing (ngs) technology have created an
unprecedented opportunity to decipher the molecular profile of tumours to more effectively …
unprecedented opportunity to decipher the molecular profile of tumours to more effectively …
[HTML][HTML] Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Tumour suppressor genes play a cardinal role in the development of a large array of human
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …
ALK testing trends and patterns among community practices in the United States
Purpose Targeted therapy of ALK in patients with metastatic nonsquamous non–small-cell
lung cancer (NSCLC) and ALK rearrangements improves outcomes compared with …
lung cancer (NSCLC) and ALK rearrangements improves outcomes compared with …
Rethinking Gamma-secretase Inhibitors for treatment of non–small-cell lung cancer: Is notch the target?
SR Pine - Clinical Cancer Research, 2018 - AACR
Lung cancer is the leading cause of cancer-related deaths among men and women. γ-
Secretase inhibitors, a class of small-molecule compounds that target the Notch pathway …
Secretase inhibitors, a class of small-molecule compounds that target the Notch pathway …
Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line–Indian consensus statement update (Under the aegis of Lung Cancer …
K Prabhash, A Vora, S Limaye, TP Sahoo… - Cancer Research …, 2021 - journals.lww.com
The management of patients with advanced non-small-cell lung cancer (NSCLC) is
becoming increasingly complex, with the identification of driver mutations/rearrangements …
becoming increasingly complex, with the identification of driver mutations/rearrangements …
Tissue-and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study
M Sposito, L Belluomini, R Nocini… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Introduction To date, for all non-small cell lung cancer (NSCLC) cases, it is recommended to
test for driver alterations to identify actionable therapeutic targets. In this light …
test for driver alterations to identify actionable therapeutic targets. In this light …